Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE: Fosaprepitant for CINV prevention
NCT00619359Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Merck & Co.. Started Feb 2008; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00619359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00619359.